肾脏替代治疗启动的个体化:AKIKI与IDEAL-ICU试验的二次分析
该研究为AKIKI与IDEAL-ICU两项随机对照试验的二次分析,纳入1107例严重急性肾损伤患者(AKIKI 619例,IDEAL-ICU 488例)。研究者建立多变量 logistic 回归模型预测延迟策略分配后48小时内启动肾脏替代治疗的风险,并用Cox模型中的样条交互项评估不同预测风险下的治疗效果。结果显示治疗效果存在异质性(P=0.023):48小时内启动肾脏替代治疗风险中高者可能从早期策略获益(绝对风险差 -14%,95%CI -27% 至 -1%);其他患者未显示早期策略获益,中低风险者呈受损趋势(绝对风险差 8%,95%CI -5% 至 21%)。作者认为这种异质性可能反映不同程度的肾脏需求-能力失配。
要点
- 在严重急性肾损伤患者中,早期与延迟启动肾脏替代治疗的治疗效果存在异质性(P=0.023)。
- 延迟策略下48小时内启动肾脏替代治疗风险中高的患者,可能从早期策略获益:绝对风险差 -14%(95%CI -27% 至 -1%)。
- 其他患者未显示早期策略获益;中低风险患者呈受损趋势:绝对风险差 8%(95%CI -5% 至 21%)。
- 该异质性可能反映不同程度的肾脏需求-能力失配。
适用人群与场景
- 严重急性肾损伤患者,数据来自AKIKI与IDEAL-ICU两项随机对照试验,共1107例(AKIKI 619例,IDEAL-ICU 488例)。
诊断标准与关键阈值
- 以多变量 logistic 回归模型预测延迟策略分配后48小时内启动肾脏替代治疗的风险,并据此分层评估治疗效果。
研究设计与关键结果
- 研究类型:AKIKI与IDEAL-ICU随机对照试验的二次分析;样本量1107例(AKIKI 619例,IDEAL-ICU 488例);人群为严重急性肾损伤患者。
- 干预与对照:早期策略对比延迟策略启动肾脏替代治疗。
- 主要终点结果:60天死亡率;治疗效果存在异质性(P=0.023)。
- 延迟策略下48小时内启动肾脏替代治疗风险中高的患者可能从早期策略获益:绝对风险差 -14%(95%CI -27% 至 -1%)。
- 其他患者未显示早期策略获益;中低风险患者呈受损趋势:绝对风险差 8%(95%CI -5% 至 21%)。
证据类型、等级与局限
- 证据类型:随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早期与延迟启动肾脏替代治疗的治疗效果异质性可能反映不同程度的肾脏需求-能力失配。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trials comparing early and delayed strategies of renal replacement therapy in patients with severe acute kidney injury may have missed differences in survival as a result of mixing together patients at heterogeneous levels of risks. Our aim was to evaluate the heterogeneity of treatment effect on 60-day mortality from an early vs a delayed strategy across levels of risk for renal replacement therapy initiation under a delayed strategy.
METHODS: We used data from the AKIKI, and IDEAL-ICU randomized controlled trials to develop a multivariable logistic regression model for renal replacement therapy initiation within 48 h after allocation to a delayed strategy. We then used an interaction with spline terms in a Cox model to estimate treatment effects across the predicted risks of RRT initiation.
RESULTS: We analyzed data from 1107 patients (619 and 488 in the AKIKI and IDEAL-ICU trial respectively). In the pooled sample, we found evidence for heterogeneous treatment effects (P = 0.023). Patients at an intermediate-high risk of renal replacement therapy initiation within 48 h may have benefited from an early strategy (absolute risk difference, - 14%; 95% confidence interval, - 27% to - 1%). For other patients, we found no evidence of benefit from an early strategy of renal replacement therapy initiation but a trend for harm (absolute risk difference, 8%; 95% confidence interval, - 5% to 21% in patients at intermediate-low risk).
CONCLUSIONS: We have identified a clinically sound heterogeneity of treatment effect of an early vs a delayed strategy of renal replacement therapy initiation that may reflect varying degrees of kidney demand-capacity mismatch.
参考来源
- Grolleau F, Porcher R, Barbar S, et al. Personalization of renal replacement therapy initiation: a secondary analysis of the AKIKI and IDEAL-ICU trials. Crit Care. 2022. PMID: 35313942. doi:10.1186/s13054-022-03936-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。